Peptides for activation and inhibition of δPKC

Details Peptides for activation and inhibition of δPKC Peptides for activation and inhibition of δPKC

2005-02-15

2005-02-15

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

06855693

ABSTRACT:
Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists.

REFERENCES:
patent: 4708871 (1987-11-01), Geysen
patent: 5776716 (1998-07-01), Ron et al.
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 6165977 (2000-12-01), Mochly-Rosen
Chen, C.H., et al.,PNAS, 96 (22): 12784-12789 (1999).
Mochly-Rosen,Science, 268: 247-251 (1995).
Mochly-Rosen, et al.,Proc. Natl. Acad. Sci. USA, 88: 3997-4000 (1991).

Affiliated with

Also associated with

Rating

Peptides for activation and inhibition of δPKC does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides for activation and inhibition of δPKC, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for activation and inhibition of δPKC will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3466639